Literature DB >> 24682968

Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy.

Maria Pia Sormani1, Nicola De Stefano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24682968     DOI： 10.1212/WNL.0000000000000369

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  4 in total

1.  CD4 cell response to interval therapy with natalizumab.

Authors:  Regina Berkovich; Daniel M Togasaki; Steven Y Cen; Lawrence Steinman
Journal:  Ann Clin Transl Neurol       Date:  2015-03-06       Impact factor: 4.511

2.  Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis.

Authors:  Luca Prosperini; Revere P Kinkel; Augusto A Miravalle; Pietro Iaffaldano; Simone Fantaccini
Journal:  Ther Adv Neurol Disord       Date:  2019-03-29       Impact factor: 6.570

Review 3.  Biology of Polyomavirus miRNA.

Authors:  Wei Zou; Michael J Imperiale
Journal:  Front Microbiol       Date:  2021-04-06       Impact factor: 5.640

4.  Viral miRNAs in plasma and urine divulge JC polyomavirus infection.

Authors:  Ole Lagatie; Tom Van Loy; Luc Tritsmans; Lieven J Stuyver
Journal:  Virol J       Date:  2014-09-02       Impact factor: 4.099
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.